Stifel maintains Buy on Boston Scientific, lowers target to $65
Stifel analyst Rick Wise has maintained a Buy rating on Boston Scientific (NYSE: BSX) while lowering the price target to $65 from $75, indicating a recalibration of potential upside despite continued confidence in the company's fundamental business strength.
*this image is generated using AI for illustrative purposes only.
Stifel analyst Rick Wise has maintained a Buy rating on Boston Scientific (NYSE: BSX) while lowering the price target to $65 from $75. The revised target indicates a recalibration of the stock's potential upside despite the positive recommendation.
The rating adjustment follows a review of the company's valuation metrics. While the analyst remains bullish on the stock's long-term prospects, the lower price target suggests a more conservative near-term trajectory.
Rating and Target Details
The following table outlines the revised analyst estimates:
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $75 |
| New Price Target | $65 |
The decision to maintain a Buy rating alongside a reduced price target highlights confidence in Boston Scientific's fundamental business strength, even as market expectations are tempered.
What specific valuation metrics prompted Stifel to lower the price target despite the Buy rating?
How might this revised price target influence investor sentiment toward Boston Scientific in the near term?
What are the key factors that could drive Boston Scientific's stock back toward the previous $75 target?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
